TNF inhibitor

Global Healthy Living Foundation to Present Pioneering Patient-Centered Research at ACR Convergence 2023

Retrieved on: 
Thursday, November 9, 2023
Biometrics, Telemedicine, Virtual Medicine, Pharmaceutical, General Health, Health, Wearables, Mobile Technology, Technology, Other Health, Online, Rheumatism, American College, Hospital, Treatment, Face, Doctor of Philosophy, Medicine, Disease, Efficacy, COVID-19, Overalls, Culture, PRO, Pain, Medical Affairs Bureau, Gold, MPH, Impact, Additive effect, RA, American College of Rheumatology, Data management, Exercise, Patient, ACR, Plant, Rehabilitation, MD, Motivation, Mindfulness, Quality of life, Longitudinal study, Research, Osteoporosis, DSM-IV codes, Guideline, Rheumatoid arthritis, Role, TNF inhibitor, Pros, Conjoint analysis, Jaki, Poster, Ageing, WEAR, Pharmaceutical industry, Medical device, Medical imaging, Nursing, Dietary supplement, Diet, Rheumatology, Fatigue, Flare, Epidemiology, Arthritis

The Global Healthy Living Foundation and its digital, arthritis patient centered research registry, formerly ArthritisPower, will collaboratively present eight scientific abstracts and five patient perspective posters at the American College of Rheumatology Convergence 2023 (Philadelphia, PA, November 10-15, 2023).

Key Points: 
  • The Global Healthy Living Foundation and its digital, arthritis patient centered research registry, formerly ArthritisPower, will collaboratively present eight scientific abstracts and five patient perspective posters at the American College of Rheumatology Convergence 2023 (Philadelphia, PA, November 10-15, 2023).
  • Collectively, GHLF researchers will focus on innovative approaches to remote therapeutic monitoring, patient engagement, and personalized care in rheumatic and musculoskeletal diseases.
  • This study offers key insights on innovative disease tracking methods, including those that can happen outside traditional clinical settings, particularly for diseases like rheumatoid arthritis (RA).
  • GHLF anticipates engaging with fellow organizations and professionals at ACR Convergence to share their year-long accomplishments in rheumatic disease research.

Press Release: Sanofi Enters Next Chapter of Play to Win Strategy

Retrieved on: 
Friday, October 27, 2023
Science, Q&A, Policy, McNeil Consumer Healthcare, Vaccine, TNF inhibitor, General Medicine Faculty of RostGMU (Rostov State Medical University), B Corporation (certification), Development, CHC, Information technology, Biopharma LLC, Growth, EPS, Medicine, Business, Research and development, Reward, Investment, Patient, Fine chemical, Pharmaceutical industry, Renewable energy, Research, Sanofi

Sanofi today provided a comprehensive update regarding its Play to Win strategy.

Key Points: 
  • Sanofi today provided a comprehensive update regarding its Play to Win strategy.
  • To that end, Sanofi announced plans to increase its R&D investments to fully realize its pipeline potential, drive long-term growth and enhance shareholder value.
  • Sanofi reiterates its financial guidance for 2023 and provides a preliminary outlook for 2024 and 2025 that reflects this new chapter of its strategy.
  • In this new chapter of our strategy, we are deepening our investment in R&D, taking steps toward becoming a pure play biopharma company, and further optimizing our cost structure.

Enable Medicine Identifies Sex-Dependent Differences in Resistance to Common Treatment for Ulcerative Colitis

Retrieved on: 
Tuesday, January 24, 2023
Cloud, UC, TNF, TNF inhibitor, Participation bias, Colitis, Atlas, Stanford University, University of California, San Diego, IBD, Female, Cancer, Science Advances, Medicine, Patient, Risk, Infection, Ulcerative colitis, Autoimmunity, Pharmaceutical industry, Medical imaging

In the paper the researchers identified cellular signatures that indicate resistance to TNF inhibitor (TNFi) therapy, the front-line treatment for ulcerative colitis (UC).

Key Points: 
  • In the paper the researchers identified cellular signatures that indicate resistance to TNF inhibitor (TNFi) therapy, the front-line treatment for ulcerative colitis (UC).
  • Combined direct and indirect costs caused by ulcerative colitis are estimated at $45 billion per year in the United States and Europe.
  • The paper identifies sex-related differences in the frequency of specific cellular signatures in untreated patients.
  • Notably, this is the most comprehensive spatial atlas of ulcerative colitis released by researchers to date.

Scipher Medicine Announces Publication of Positive Results From AIMS Clinical Study

Retrieved on: 
Friday, November 11, 2022
Health, Other Health, Clinical Trials, Research, Science, Biotechnology, Rheumatoid arthritis, Division, AIMS, Sickle Cell Anemia, a Molecular Disease, Cardiovascular disease, MPH, Disulfiram-like drug, Risk, Adoption, Death, Rheumatology, Immunology, Precision medicine, Medicine, Degenerative disease, Computer science, Goal, Solution, Cancer, Standard of care, Epidemiology, University, Patient, Therapy, Expert Review of Hematology, RA, University of Alabama at Birmingham School of Medicine, SOC, TNF inhibitor, Pharmaceutical industry, Facebook, MD

Scipher Medicine announced data validating the clinical utility of the companys PrismRA test for guiding treatment selection for rheumatoid arthritis (RA) patients.

Key Points: 
  • Scipher Medicine announced data validating the clinical utility of the companys PrismRA test for guiding treatment selection for rheumatoid arthritis (RA) patients.
  • The latest publication in the Expert Review of Molecular Diagnostics showed that patients whose care included PrismRA testing had significantly superior clinical outcomes when compared to current standard of care (SOC).
  • We partner with leading payers, healthcare providers, and pharmaceutical companies to bring precision medicine solutions to patients with autoimmune diseases.
  • Visit sciphermedicine.com and follow Scipher Medicine on Twitter, Facebook, and LinkedIn.

Scipher Medicine Publishes New Data Further Supporting Clinical Utility of PrismRA Blood Test

Retrieved on: 
Thursday, April 28, 2022
FDA, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Stanford University School of Medicine, Solution, CDAI, LinkedIn, RA, Biotechnology, Patient, Twitter, Pharmacy, TNF inhibitor, Division, Degenerative disease, Immunotherapy, Expert Opinion on Biological Therapy, Therapy, Precision medicine, Rheumatoid arthritis, Sickle Cell Anemia, a Molecular Disease, Immunology, Pharmaceutical industry, Medicine, Rheumatology, Facebook

After six months, RA patients with moderate and high disease activity whose treatment was guided by PrismRA, showed a nearly two-fold clinical improvement in Clinical Disease Activity Index (CDAI) scores compared to patients whose therapy was not guided by PrismRA results.

Key Points: 
  • After six months, RA patients with moderate and high disease activity whose treatment was guided by PrismRA, showed a nearly two-fold clinical improvement in Clinical Disease Activity Index (CDAI) scores compared to patients whose therapy was not guided by PrismRA results.
  • These data add to the growing evidence supporting the clinical utility of the PrismRA test to inform treatment selection for patients with RA.
  • PrismRA is a revolutionary blood test bringing precision medicine to the treatment of rheumatoid arthritis, which affects 20 million patients globally.
  • Scipher Medicine, a precision immunology company matching each patient with their most effective therapy, believes that patients deserve simple answers to treatment options based on scientific data.

Revive Therapeutics Announces Publication of Research Data with Bucillamine in COVID-19

Retrieved on: 
Monday, April 18, 2022
CSE, Patient, Rituximab, TNF inhibitor, MMF, TNF, CNI, Research, RVV, Modern Rheumatology, Rheumatology, Vaccine, Therapy, Abatacept, GLOBE, MTX, Cyclophosphamide, Methotrexate, Sulfasalazine, Disorder, Severe acute respiratory syndrome coronavirus 2, Pharmaceutical industry, Fertilizer, Bucillamine

The newly published study further validates the potential of Bucillamine in the treatment course for COVID-19.

Key Points: 
  • The newly published study further validates the potential of Bucillamine in the treatment course for COVID-19.
  • The potential of Bucillamine for COVID-19 is evident with its anti-inflammatory and antiviral properties and its potential use in patients who have taken SARS-CoV-2 mRNA vaccines, said Michael Frank, CEO of Revive.
  • Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and COVID-19.
  • With its acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders.

Scipher Medicine Closes $110 Million Financing

Retrieved on: 
Thursday, February 24, 2022
General Health, Finance, Health, Professional Services, Pharmaceutical, Therapy, Sickle Cell Anemia, a Molecular Disease, Degenerative disease, Twitter, CFA, Khosla Ventures, Research, Medicine, Precision medicine, TNF inhibitor, LinkedIn, Rheumatoid arthritis, Bone erosion, Autoimmune disease, Patient, Solution, CEO, Pharmaceutical industry, Facebook

Scipher Medicine , a precision immunology company matching each patient with their most effective therapy, today announced the completion of a $110 million financing.

Key Points: 
  • Scipher Medicine , a precision immunology company matching each patient with their most effective therapy, today announced the completion of a $110 million financing.
  • To date, Scipher has raised $227 million.
  • Scipher Medicine, a precision immunology company matching patients with their most effective therapy, believes that patients deserve simple answers to treatment options based on scientific data.
  • Visit http://www.sciphermedicine.com and follow Scipher Medicine on Twitter, Facebook, and LinkedIn.

Scipher Medicine Announces Publication of Real-World Study Demonstrating Clinical Utility of PrismRA® Blood Test

Retrieved on: 
Tuesday, February 1, 2022
General Health, Science, Health, Research, Joint, Molecular diagnostics, Patient, Health, University, Immunology, RA, Trial of the century, Rheumatoid arthritis, Twitter, Arthritis, Adoption, Woman, Autoimmunity, Degenerative disease, Man, Disease, TNF inhibitor, Precision medicine, Bone erosion, Arthritis Foundation, Stanford University, Time, University of Alabama, Texas Health Presbyterian Hospital Dallas, Division, FDA, Inflammation, Therapy, LinkedIn, Stanford University School of Medicine, Sickle Cell Anemia, a Molecular Disease, AIMS, Solution, Pharmaceutical industry, Rheumatology, Facebook, Medicine, PrismRA®, Scipher Medicine®, PRISMRA®, SCIPHER MEDICINE®

PrismRA is the only blood test in the market informing personalized treatment decisions for patients with RA.

Key Points: 
  • PrismRA is the only blood test in the market informing personalized treatment decisions for patients with RA.
  • According to the study, patients whose treatment was guided by PrismRA experienced three times better clinical response compared to patients whose therapy selection was not guided by PrismRA results.
  • Study results also suggest that PrismRA has high clinical utility, providing individualized patient information that guided physician therapy selection in 74% of patients.
  • PrismRA is a revolutionary blood test bringing precision medicine to the treatment of rheumatoid arthritis, which affects 20 million patients globally.

Advisory - Health Canada safety review finds link between the use of Xeljanz and Xeljanz XR (tofacitinib) and increased risk of serious heart-related issues and cancer

Retrieved on: 
Wednesday, January 12, 2022
Pulmonary embolism, Minister of Health (Canada), Immunodeficiency, Lung, Patient, Sepsis, Lymphoma, Inflammation, Sores, Bleeding, Clinical trial, Vein, Infarction, Smoker, Pfizer, Psoriatic arthritis, Degenerative disease, DVT, Fever, Safety, Opportunistic infection, Health Canada, Death, Arm, Cough, Tenderness, Joint, Health care, Leg, Cancer, Review, Ulcerative colitis, Swelling, Malignancy, Artery, Pain, Skin, Infection, Perspiration, Chills, TNF inhibitor, Chest pain, Sale, Risk, Rheumatoid arthritis, Lung cancer, Thrombosis, Frankincense, Dietary supplement, Pharmaceutical industry, Health insurance, Birth control, Medical device, Healthcare, Tofacitinib, Upadacitinib

Issue:Health Canada's safety review found a link between the use of Xeljanz and Xeljanz XR (tofacitinib) and the risks of serious heart-related issues and cancer.

Key Points: 
  • Issue:Health Canada's safety review found a link between the use of Xeljanz and Xeljanz XR (tofacitinib) and the risks of serious heart-related issues and cancer.
  • What to do:Do not stop or change your dose of Xeljanz or Xeljanz XR (tofacitinib) without first talking to your healthcare professional.
  • Do not stop or change your dose of Xeljanz or Xeljanz XR (tofacitinib) without first talking to your healthcare professional.
  • Follow the recommendations in the Xeljanz and Xeljanz XR (tofacitinib) product monograph for the specific condition you are treating.

Nearly 15% of Prescribing U.S. Rheumatologists Use Scipher Medicine’s PrismRA® Blood Test Since Its Launch A Year Ago

Retrieved on: 
Monday, December 6, 2021
Biotechnology, Pharmaceutical, Health, Medical Devices, Patient, Man, Degenerative disease, Rheumatology, Bone erosion, Multiple sclerosis, Woman, MD, Rheumatoid arthritis, Precision medicine, Autoimmunity, TNF inhibitor, Solution, RA, Therapy, Arthritis, Physician, Medicine, Arthritis Foundation, Twitter, Ulcerative colitis, Health, HIV disease progression rates, FDA, Inflammation, Sickle Cell Anemia, a Molecular Disease, LinkedIn, Joint, Quality of life, Pharmaceutical industry, PrismRA®, Scipher Medicine®, PRISMRA®, SCIPHER MEDICINE®

PrismRA is the only blood test in the market informing personalized treatment decisions for patients with rheumatoid arthritis (RA).

Key Points: 
  • PrismRA is the only blood test in the market informing personalized treatment decisions for patients with rheumatoid arthritis (RA).
  • PrismRA identifies patients unlikely to respond to TNFi drugs, enabling non-responders to be prescribed alternative FDA-approved therapy from day one that could significantly improve clinical outcomes.
  • Rheumatologists, their patients, and healthcare stakeholders are responding very positively to PrismRA, said Sam Asgarian, M.D., chief medical officer of Scipher Medicine.
  • PrismRA is a revolutionary blood test bringing precision medicine to the treatment of rheumatoid arthritis, which affects 20 million patients globally.